http://www.forbes.com/2009/07/21/gsk-swine-flu-markets-equity-earnings.html
"The new flu strain can be treated by antivirals such as GlaxoSmithKline's Relenza, which may provide with up to 350 million pounds ($573 million) in sales, according to some estimates."
573m x 7% = 40.11m (USD) = 49.3m (AUD)